COVID-19 疫苗：免疫原性、安全性的现有认识及进一步的考虑因素。
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.
机构信息
National Institutes for Food and Drug Control, Beijing, China.
出版信息
Front Immunol. 2021 Apr 12;12:669339. doi: 10.3389/fimmu.2021.669339. eCollection 2021.
Abstract
The world has entered the second wave of the COVID-19 pandemic, and its intensity is significantly higher than that of the first wave of early 2020. Many countries or regions have been forced to start the second round of lockdowns. To respond rapidly to this global pandemic, dozens of COVID-19 vaccine candidates have been developed and many are undergoing clinical testing. Evaluating and defining effective vaccine candidates for human use is crucial for prioritizing vaccination programs against COVID-19. In this review, we have summarized and analyzed the efficacy, immunogenicity and safety data from clinical reports on different COVID-19 vaccines. We discuss the various guidelines laid out for the development of vaccines and the importance of biological standards for comparing the performance of vaccines. Lastly, we highlight the key remaining challenges, possible strategies for addressing them and the expected improvements in the next generation of COVID-19 vaccines.
摘要
世界已进入 COVID-19 大流行的第二波，其强度明显高于 2020 年初的第一波。许多国家或地区被迫启动第二轮封锁。为了快速应对这一全球大流行，已经开发出数十种 COVID-19 疫苗候选物，其中许多正在进行临床试验。评估和确定对人类使用有效的疫苗候选物对于优先考虑针对 COVID-19 的疫苗接种计划至关重要。在这篇综述中，我们总结和分析了不同 COVID-19 疫苗的临床报告中关于疗效、免疫原性和安全性的数据。我们讨论了制定疫苗的各种指导方针以及比较疫苗性能的生物标准的重要性。最后，我们强调了关键的遗留挑战、可能的解决策略以及下一代 COVID-19 疫苗的预期改进。
相似文献
1
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations.COVID-19 疫苗：免疫原性、安全性的现有认识及进一步的考虑因素。
Front Immunol. 2021 Apr 12;12:669339. doi: 10.3389/fimmu.2021.669339. eCollection 2021.
2
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.COVID-19 疫苗：紧跟 SARS-CoV-2 变异株。
Cell. 2021 Sep 30;184(20):5077-5081. doi: 10.1016/j.cell.2021.09.010. Epub 2021 Sep 17.
3
A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.《COVID-19 疫苗研发的进展与挑战综述》。
Front Immunol. 2020 Oct 14;11:585354. doi: 10.3389/fimmu.2020.585354. eCollection 2020.
4
Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines.辉瑞和阿斯利康 COVID-19 疫苗的反应原性和免疫原性。
Front Immunol. 2021 Dec 1;12:794642. doi: 10.3389/fimmu.2021.794642. eCollection 2021.
5
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.什么是有效的 COVID-19 疫苗？评估针对 SARS-CoV-2 的疫苗临床疗效的挑战综述。
Lancet Infect Dis. 2021 Feb;21(2):e26-e35. doi: 10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27.
6
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.安全性、免疫原性和异源加强用 SARS-CoV-2 mRNA 疫苗（SYS6006）在中国 18 岁及以上人群中的效果：一项随机、开放标签、阳性对照的 3 期临床试验。
Emerg Microbes Infect. 2024 Dec;13(1):2320913. doi: 10.1080/22221751.2024.2320913. Epub 2024 Feb 29.
7
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
8
COVID-19 vaccines: the importance of transparency and fact-based education.新冠疫苗：透明度和基于事实的教育的重要性。
Br J Clin Pharmacol. 2020 Nov;86(11):2107-2110. doi: 10.1111/bcp.14581. Epub 2020 Oct 14.
9
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎疫苗的有效性、免疫原性和安全性的系统评价和荟萃分析。
Front Immunol. 2021 Oct 11;12:714170. doi: 10.3389/fimmu.2021.714170. eCollection 2021.
10
Coronavirus disease 2019 vaccination in transplant recipients.新型冠状病毒病 2019 疫苗接种在移植受者中的应用。
Curr Opin Infect Dis. 2021 Aug 1;34(4):275-287. doi: 10.1097/QCO.0000000000000739.
引用本文的文献
1
Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia.mRNA、病毒载体和灭活新冠疫苗的安全性比较：马来西亚医疗专业人员中初次接种和加强剂量后不良事件的发生率
BMC Infect Dis. 2025 Jul 7;25(1):898. doi: 10.1186/s12879-025-11254-1.
2
Recent development of oral vaccines (Review).口服疫苗的最新进展（综述）
Exp Ther Med. 2024 Mar 22;27(5):223. doi: 10.3892/etm.2024.12511. eCollection 2024 May.
3
Impact of the SARS-CoV-2 Vaccination Program on Presenteeism and Absenteeism among Healthcare Workers in Poland.新冠病毒疫苗接种计划对波兰医护人员出勤主义和旷工现象的影响。
Vaccines (Basel). 2023 Dec 24;12(1):23. doi: 10.3390/vaccines12010023.
4
Influence of COVID-19 infection/vaccination on menstrual regularity and hormonal function in Saudi females of reproductive age.新型冠状病毒肺炎感染/疫苗接种对沙特育龄女性月经规律和激素功能的影响。
Heliyon. 2023 Nov 17;9(11):e22291. doi: 10.1016/j.heliyon.2023.e22291. eCollection 2023 Nov.
5
Effects of Antibodies in the Serum After the Administration of COVID Vaccines and Their Hematological and Cardiovascular Complications.新冠疫苗接种后血清中抗体的作用及其血液学和心血管并发症
Cureus. 2023 Oct 30;15(10):e47984. doi: 10.7759/cureus.47984. eCollection 2023 Oct.
6
7
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.一种针对新型冠状病毒的重组蛋白RBD融合异二聚体疫苗的安全性和免疫原性
NPJ Vaccines. 2023 Sep 29;8(1):147. doi: 10.1038/s41541-023-00736-5.
8
Text classification technique for discovering country-based publications from international COVID-19 publications.从国际新冠肺炎出版物中发现基于国家的出版物的文本分类技术。
Digit Health. 2023 Jul 3;9:20552076231185674. doi: 10.1177/20552076231185674. eCollection 2023 Jan-Dec.
9
The Matrix-M™ adjuvant: A critical component of vaccines for the 21 century.Matrix-MTM 佐剂：21 世纪疫苗的关键组成部分。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885. Epub 2023 Apr 27.
10
Combination of Recombinant Proteins S1/N and RBD/N as Potential Vaccine Candidates.重组蛋白S1/N和RBD/N组合作为潜在候选疫苗
Vaccines (Basel). 2023 Apr 18;11(4):864. doi: 10.3390/vaccines11040864.
本文引用的文献
1
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
2
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
3
SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）501Y.V2变体的传染性并不更强，但确实存在免疫逃逸。
Cell. 2021 Apr 29;184(9):2362-2371.e9. doi: 10.1016/j.cell.2021.02.042. Epub 2021 Feb 23.
4
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.科维希尔德腺病毒载体新冠疫苗（ChAdOx1 nCoV-19）对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1885-1898. doi: 10.1056/NEJMoa2102214. Epub 2021 Mar 16.
5
A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.一种基于蛋白质组学的免疫信息学工具，用于加速新兴传染病背景下的 T 细胞表位发现和疫苗设计：一种面向种族的方法。
Front Immunol. 2021 Feb 26;12:598778. doi: 10.3389/fimmu.2021.598778. eCollection 2021.
6
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.SARS-CoV-2 变异株 B.1.1.7 易被原始刺突疫苗诱导产生的中和抗体中和。
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.
7
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
8
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.南非新冠病毒 501Y.V2 变异株可逃避南非捐赠者血浆的中和作用。
Nat Med. 2021 Apr;27(4):622-625. doi: 10.1038/s41591-021-01285-x. Epub 2021 Mar 2.
9
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates.S-三聚体疫苗，一种 COVID-19 亚单位候选疫苗，可诱导非人灵长类动物产生保护性免疫。
Nat Commun. 2021 Mar 1;12(1):1346. doi: 10.1038/s41467-021-21634-1.
10
Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.COVID-19 疫苗的免疫学替代终点：我们现有的证据与我们所需的证据。
Signal Transduct Target Ther. 2021 Feb 2;6(1):48. doi: 10.1038/s41392-021-00481-y.
Zotero 插件